	SCIg							Lyophilized IVIg
	Cuvitru™	Gammagard® Liquid	Gammaked®	Gamunex-C®	Hizentra™	Xembify®	HyQvia™	Gammagard® S/D with IgA <1 mcg/mL
Form	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Lyophilized
Infusion Route	Subcutaneous	Subcutaneous	Subcutaneous	Subcutaneous	Subcutaneous	Subcutaneous	Subcutaneous	Intravenous
Manufacturer	Shire (formerly Baxalta)	Shire (formerly Baxalta)	Kedrion	Grifols	CSL Behring	Grifols	Shire (formerly Baxalta)	Shire (formerly Baxalta)
Clinical Contact	1-866-424-6724	1-866-424-6724	1-855-353-7466	1-800-520-2807	1-800-504-5434	1-800-520-2807	1-866-424-6724	1-866-424-6724
Labeled Uses	PIDD	PIDD	PIDD	PIDD	PIDD, CIDP	PIDD	PIDD	PIDD, ITP, CLL, Kawasaki disease
Vial Sizes	1 g, 2 g, 4 g, 8 g	1 g, 2.5 g, 5 g, 10 g, 20 g, 30 g	1 g, 2.5 g, 5 g, 10 g, 20 g	1 g, 2.5 g, 5 g, 10 g, 20 g	1gm (5mL), 2gm (10mL), 4gm (20mL), 10gm (50mL)	1 g, 2 g, 4 g, 10 g	2.5 g/200 U, 5 g/400 U, 10 g/800 U, 20 g/1,600 U, 30 g/2,400 U	5 g, 10 g
Diluent	N/A	N/A	N/A	N/A	N/A	N/A	N/A	• Sterile water • 96 mL for 5 gm 5% • 192 mL for 10 gm 5%
Concentration	20%	10%	10%	10%	20%	20%	10%	• 5% • 10%: Use half diluent supplied
Infusion Rate (*Refer to package insert for renally-compromised or high-risk patients)	May administer in up to 4 sites simultaneously. **First 2 infusions:** < 40 kg administer ≤ 20 ml/site at rate of 10-20 mL/hr/site ≥ 40 kg administer ≤ 60 mL/site at rate of 10-20 mL/hr/site **Subsequent infusions (all weights):** Administer ≤ 60 mL/site at rate of ≤ 60 mL/hr/site	**40 kg BW and greater:** First infusion 30 mL/site at a rate of 20 mL/hr/site. Subsequent doses may be increased to 30 mL/site at a rate of 20–30 mL/hr/site. Maximum flow rate not to exceed 240 mL/hr for all sites combined. **Under 40 kg BW:** First infusion 20 mL/site at a rate of 15 mL/hr/site. Subsequent doses may be increased to 20 mL/site at a rate of 15–20 mL/hr/site. Maximum flow rate not to exceed 160 mL/hr for all sites combined.	20 mL/hr/site	20 mL/hr/site	First infusion 15 mL/hr/site. Subsequent doses may be increased to a maximum of 25 mL/hr/site as tolerated. Maximum flow rate not to exceed a total of 50 mL/hr for all sites combined. May be less in pediatric patients (5–10 mL/hr).	May administer up to 6 infusion sites simultaneously at a maximum rate of 25 mL/hr/site	Refer to package insert; Initial and max rate is based on weight and number of infusions received. Infusion rates may be increased every 5–15 mins as tolerated. Initial rate range: 5–10 mL/hr/site. Max rate: 300 mL/hr/site.	• 5%: 0.5 mL/kg/hr and may increase gradually to a maximum of 4 mL/kg/hr if no adverse reaction* • High-risk patients: Maximum rate of 4 mL/kg/hr at 5%* • May use 10% (if 5% tolerated)* • 0.5 mL/kg/hr and may increase gradually to 8 mL/kg/hr*
Sugar Content	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	Sugar free; stabilized with L-proline	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	2% glucose
Sodium Content	N/A	N/A	Trace amounts	Trace amounts	Trace amounts	Trace amounts	N/A	0.85% with 5%
Osmolality/ Osmolarity	280–292 mOsm/kg	240–300 mOsm/kg	258 mOsm/kg	258 mOsm/kg	380 mOsm/kg	280 to 404 mOsmol/kg	240–300 mOsm/kg	5%: 636 mOsm/kg
pH	4.6–5.1	4.6–5.1	4–4.5	4–4.5	4.6–5.2	4.1–4.8	4.6–5.1	6.8 ±0.4 (after reconstitution)
IgA Content	80 mcg/mL	37 mcg/mL	46 mcg/mL	46 mcg/mL	<50 mcg/mL	<70 µg/mL	37 mcg/mL	<1 mcg/mL
% IgG	≥ 98%	>98%	>98%	>98%	≥98%	>98%	>98%	>90%
Latex Content	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Packaging contains latex
Method of Production and Viral Inactivation/ Removal Process	Cold ethanol fractionation, cation and anion exchange chromatography, solvent/detergent (S/D) treatment, 35 nm nanofiltration, low pH incubation at elevated temperature	Cold ethanol fractionation, 35 nm nanofiltration, chromatography, low pH incubation, solvent/ detergent treatment	Depth filtration, cold ethanol fractionation, chromatography, low pH treatment, caprylate precipitation	Depth filtration, cold ethanol fractionation, chromatography, low pH treatment, caprylate precipitation	Depth filtration, cold alcohol fractionation, octanoic acid fractionation, chromatography, pH4 incubation, 20 nm nanofiltration	Cold ethanol fractionation, caprylate precipitation and filtration, and anion-exchange chromatography	Cold ethanol fractionation, S/D treatment, 35 nm nanofiltration, low pH incubation	Cold ethanol fractionation, ultrafiltration, chromatography, solvent/detergent treatment
Filtration	No filter required	In-line filter optional	No filter required	No filter required	No filter required	No filter needed	No filter required	Filter required
Flushing Compatibility	N/A	Saline or dextrose	Dextrose only, not compatible with saline	Dextrose only, not compatible with saline	N/A	Dextrose if needed	Saline	Saline or dextrose
Storage Requirements	• Refrigerate or room temperature • Do not freeze	• Refrigerate or room temperature • Do not freeze	• Refrigerate or room temperature • Do not freeze	• Refrigerate or room temperature • Do not freeze	• Room temperature (≤25°C, 77°F) • Do not freeze • Protect from light	• 2°C–8°C • Do not freeze	• Refrigerate • Do not freeze	• Room temperature (≤25°C, 77°F) • Do not freeze
Shelf Life	36 months refrigerated at 2°C–8°C (36°F–46°F), or up to 12 months at room temperature up to 25°C or 77°F	36 months refrigerated at 2°–8°C (36°–46°F), or 12 months at room temp (≤ 25°C, 77°F) within first 24 months of manufacture date	36 months refrigerated at 2°C–8°C (36°F–46°F), or 6 months at room temp (≤25°C, 77°F) any time during the 36 months	36 months refrigerated at 2°C–8°C (36°F–46°F), or 6 months at room temp (≤25°C, 77°F) any time during the 36 months	Stable for the period indicated by the expiration date on label. Preservative-free	May be stored at temperatures not to exceed 25°C (77°F) for up to 6 months any time prior to the expiration date	24 months from date of manufacture refrigerated at 2°C–8°C (36°F–46°F)	24 months, preservative free

Immunoglobulin Comparison Chart

Contact us today to learn how we can help support your Ig therapy patients.

Phone 1-866-899-1661 | Fax 1-866-843-3221

Glossary

CIDP ..... Chronic inflammatory demyelinating polyneuropathy
CLL ..... Chronic lymphocytic leukemia
Ig ..... Immunoglobulin
IgA ..... Immunoglobulin A
IgG ..... Immunoglobulin G
ITP ..... Immune thrombocytopenic purpura
IV ..... Intravenous
IVIg ..... Intravenous Immunoglobulin
MMN ..... Multifocal motor neuropathy
NaCl ..... Sodium chloride; saline
PIDD ..... Primary immunodeficiency disease
pH ..... Potential of hydrogen
SCIg ..... Subcutaneous immunoglobulin

[1]Maltose can interfere with the readings of some blood glucose monitoring systems up to 24–36 hours post-dose.

CVS specialty®

Coram®
CVS specialty® infusion services

	Liquid IVIg								
	Flebogamma® DIF	**Gammagard® Liquid**	**Gammaked®**	**Gammaplex®**	**Gamunex-C®**	**Bivigam®**	**Panzyga®**	**Octagam®**	**Privigen™**
Form	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid
Infusion Route	Intravenous	Intravenous	Intravenous	Intravenous	Intravenous	Intravenous	Intravenous	Intravenous	Intravenous
Manufacturer	Grifols	Shire (formerly Baxalta)	Kedrion	Bio Products Laboratory	Grifols	ADMA	Pfizer	Octapharma	CSL Behring
Clinical Contact	1-888-474-3657	1-866-424-6724	1-855-353-7466	1-800-843-7477	1-800-520-2807	1-800-458-4244	1-888-429-4535	1-888-429-4535	1-800-504-5434
Labeled Uses	PIDD	PIDD, MMN	CIDP, PIDD, ITP	PIDD, ITP	CIDP, PIDD, ITP	PIDD	PI (age ≥ 2), chronic ITP (adults)	PIDD	PIDD, ITP, CIDP
Dosing Sizes	• 5%: 0.5 g, 2.5 g, 5 g, 10 g, 20 g • 10%: 5 g, 10 g, 20 g	1 g, 2.5 g, 5 g, 10 g, 20 g, 30 g	1 g, 2.5 g, 5 g, 10 g, 20 g	• 5%: 5 g, 10 g, 20 g • 10%: 5 g, 10 g, 20 g	1 g, 2.5 g, 5 g, 10 g, 20 g	5 g, 10 g	2.5 g, 5 g, 10 g, 20 g, 30 g	• 5%:1 g, 2.5 g, 5 g, 10 g, 25 g • 10%: 2 gm, 5 gm, 10 gm, 20 gm	5 g, 10 g, 20 g, 40 g
Diluent	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Concentration	5%, 10%	10%	10%	5%, 10%	10%	10%	10%	10%	10%
Infusion Rate (*Refer to package insert for renally-compromised or high-risk patients)	• 5%: 0.01 mL/kg/min for 30 min, then increase gradually to rate of 0.10 mL/kg/min as tolerated. At risk patients — rate less than 0.06 mL/kg/min.* • 10%: 0.01 mL/kg/min; if no adverse reactions, can slowly increase subsequent infusions to 0.08 mL/kg/min*	0.5 mL/kg/hr; rate can be increased every 30 min to a rate of 5 mL/kg/hr as tolerated*	0.01 mL/kg/min for 30 min; can be gradually increased to a maximum of 0.08 mL/kg/min if no adverse reaction*	• 5%: 0.5 mg/kg/min for the first 15 min; if tolerated, gradually increase to 4 mg/kg/min* • 10%: 0.5 mg/kg/min for the first 15 min; if tolerated, gradually increase to 8 mg/kg/min*	0.01 mL/kg/min for 30 min; can be gradually increased to a maximum of 0.08 mL/kg/min if no adverse reaction*	• Initial Infusion Rate: 0.5 mg/kg/min for the first 10 minutes • Maintenance Infusion Rate (if tolerated): Increase every 20 minutes (if tolerated) by 0.8 mg/kg/min up to 6 mg/kg/min	• Initial Infusion Rate: 1 mg/kg/min (0.01 mL/kg/min) • Maximum Infusion Rate (new patients): 8 mg/kg/min (0.08 mL/kg/min) • Maximum Infusion Rate (experienced patients): 12 or 14 mg/kg/min (0.12 or 0.14 mL/kg/min)	• 5%: 0.6 mL/kg/hr for 30 min, then advance to 1.2 mL/kg/hr for 30 min, then advance to 2.4 mL/kg/hr for 30 min. Maximum rate at 4 mL/kg/hr for the remainder of the infusion.* • 10%: 1.0 mg/kg/min (0.01 mL/kg/min) up to 12.0 mg/kg/min (Up to 0.12 mL/kg/min)*	• PIDD: 0.5 mg/kg/min (0.005 mL/kg/min); if well tolerated, may increase gradually to 8 mg/kg/min (0.08 mL/kg/min)* • ITP: 0.5 mg/kg/min (0.005 mL/kg/min); if well tolerated, may increase gradually to 4 mg/kg/min (0.04 mL/kg/min)*
Sugar Content	5%, 10% D-Sorbitol	Sugar free; stabilized with glycine	Sugar free; stabilized with glycine	• 5%: 5 g D-Sorbitol in 100 mL of buffer solution • 10%: Sugar free, stabilized with glycine and polysorbate 80	Sugar free; stabilized with glycine	No added sugars	Glycine	100 mg/mL maltose[1]	Sugar free; stabilized with L-proline
Sodium Content	• 5%: <3.2 mmol/L • 10%: Trace	N/A	Trace amounts	• 5%: 0.2 g sodium acetate and 0.3 g sodium chloride in 100 mL of buffer solution • 10%: <30 mM sodium chloride in 100 mL of buffer solution	Trace amounts	100 –140 mmol/L	Trace amounts	<30 mmol/L	<1 mmol/L (10 % solution)
Osmolality/ Osmolarity	240–370 mOsm/kg	240–300 mOsm/kg	258 mOsm/kg	• 5%: Typically 420-500 mOsm/kg (not less than 240 mOsm/kg) • 10%: Typically 280 mOsm/kg (not less than 240 mOsm/kg)	258 mOsm/kg	≤ 510 mOsm/kg	240-310 mOsmol/kg	310–380 mOsm/kg	320 mOsm/kg (range 240–440)
pH	5–6	4.6–5.1	4–4.5	• 5%: 4.8-5.1 • 10%: 4.9-5.2	4–4.5	4.0–4.6	4.5–5.0	5–6	4.8 (range 4.6–5)
IgA Content	• 5%: <50 mcg/mL • 10%: <100 µg/mL	37 mcg/mL	46 mcg/mL	• 5%: <10 µg/mL • 10%: <20 µg/mL	46 mcg/mL	≤ 200 µg/mL	Average 100 µg/mL	≤200 mcg/mL	<25 mcg/mL
% IgG	>97%	>98%	>98%	• 5%: >95% • 10%: >98%	>98%	>96%	>96%	>96%	>98%
Latex Content	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free	Latex free
Method of Production and Viral Inactivation/ Removal Process	Cold ethanol fractionation, PEG precipitation, sequential 35 nm + 20 nm nanofiltration, chromatography, pasteurization, low pH treatment, solvent/detergent treatment	Cold ethanol fractionation, 35 nm nanofiltration, chromatography, low pH incubation, solvent/detergent treatment	Depth filtration, cold ethanol fractionation, chromatography, low pH treatment, caprylate precipitation	S/D treatment, virus filtration, pH incubation	Depth filtration, cold ethanol fractionation, chromatography, low pH treatment, caprylate precipitation	Cohn-Oncley fractionation, anion exchange chromatography; precipitation and removal of fraction III of the cold ethanol process, solvent/detergent treatment, 35nm nanofiltration	Cold ethanol fractionation process followed by purification methodologies, as well as S/D treatment and nanofiltration (20 nm)	Low pH incubation, solvent/ detergent treatment, cold ethanol fractionation	• Depth filtration, cold ethanol fractionation, octanoic acid fractionation, chromatography, • pH4 incubation, 20 nm nanofiltration
Filtration	Filter recommended	In-line filter optional	No filter required	No filter required	No filter required	No filter required	In-line 0.2 micron filter required	In-line 0.2 micron filter optional	No filter required
Flushing Compatibility	Saline or dextrose	Saline or dextrose	Saline or dextrose	Saline or dextrose	Saline or dextrose	Saline	Saline or dextrose	Saline or dextrose	Saline or dextrose
Storage Requirements	• 2ºC–25ºC • Protect from light • Do not freeze	• Refrigerate or room temperature • Do not freeze	• Refrigerate or room temperature • Do not freeze	• Refrigerate or room temperature • Do not freeze	• Refrigerate or room temperature • Do not freeze	• 2°C–8°C • Do not freeze	• 2°C–8°C • Do not freeze	• Room temperature • Do not freeze • Protect from light	• Room temperature • Do not freeze • Protect from light
Shelf Life	24 months, preservative free, room temp — not to exceed 25ºC (77ºF) until expiration date. Preservative free.	36 months refrigerated at 2Cº–8ºC (36Fº–46ºF), or 12 months at room temp (≤25ºC, 77ºF) within first 24 months of the manufacture date	36 months refrigerated at 2º–8º C (36ºF–46ºF), or 6 months at room temp (≤25ºC, 77ºF) any time during the 36 months	36 months, when stored between 2ºC [35.6ºF] and 25ºC [77ºF]	36 months refrigerated at 2ºC–8ºC (36ºF–46ºF), or 6 months at room temp (≤25ºC, 77ºF) any time during the 36 months	24 months (refrigerated)	24 months at 2°C to 8°C (36°F to 46°F) from the date of manufacture. Within its shelf-life, the product may be stored at ≤ 25°C (77°F) for up to 9 months	24 months, preservative free	36 months, preservative free